EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, today announced the appointment of Robert Truckenmiller as Senior Vice President, Market Access & Customer Solutions. In this role, Mr. Truckenmiller will oversee the development of U.S. market access strategy and implementation, as well as payer contracting and reimbursement strategies, to enable patient access to EMD Serono medications.
Mr. Truckenmiller joined EMD Serono in July 2016 as Vice President, Market Access & Customer Solutions, where he implemented new processes and procedures to optimize development and operations of all EMD Serono contracted business.
"Rob has demonstrated tremendous knowledge of the payer landscape, offering strategic insights and creating processes to ensure patients receive the medications they need," said Gary Zieziula, President and Managing Director of EMD Serono. "With his strong track record, I know Rob will successfully lead EMD Serono in delivering meaningful therapies to people with difficult to treat diseases."
Prior to EMD Serono, Mr. Truckenmiller served as Vice President and Head of U.S. Market Access & Pricing at UCB, where he led a large team in developing a market access strategy that successfully improved overall patient access to UCB brands. He spent eleven years at UCB, taking on roles of increasing responsibility across market access and brand marketing. Additionally, Rob has more than 15 years of experience in the biopharmaceutical industry in various sales and marketing roles at companies such as Johnson & Johnson and DaVita Kidney Care.
Mr. Truckenmiller succeeds Scott Filosi, who was recently appointed to a new position within Merck KGaA, Darmstadt, Germany, as the Head of Global Market Access & Pricing.
Mr. Truckenmiller holds an undergraduate degree in Marketing and an MBA in Finance and Financial Management Services from University of Central Florida - College of Business Administration.
About EMD Serono, Inc.
EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has 1,300 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts. www.emdserono.com
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of € 15.0 billion in 66 countries. Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
